An analytical database, using high-performance liquid chromatography (HPLC) with diode array ultraviolet (UV) detection, of over 250 toxicologically relevant drugs has been extensively applied to both clinical and forensic toxicology. This general drug screening system, based on a mixed-phase (octadecyl/cyanopropyl) column and gradient reversed-phase HPLC, can identify a wide range of basic, acidic, and neutral drugs and metabolites, some of which are not amenable to gas chromatography and thin-layer chromatography. Compounds are identified using both retention index (RI) value (calculated by interpolation between a series of reference drug markers) and UV spectral data. It has been previously shown that this chromatographic system provides long-term reproducibility and has potentially useful selectivity differences compared with those based on octadecylsilane columns. Development has been undertaken to improve the speed and practicality of the system for emergency toxicology screening by increasing the rate of the elution gradient, while maintaining the applicability of the RI database. The database has also been found to be an important tool in determining optimum strategies for the adaptation of the system for quantitative analyses of drugs and metabolites under isocratic conditions.
Introduction
There are a number of established chromatographic techniques available to clinical and forensic toxicologists, such as thin-layer chromatography (TLC), gas chromatography (GC), and high-performance liquid chromatography (HPLC). In addition, coupling GC and HPLC with a mass spectrometer (MS) has enhanced the effectiveness of these techniques for general toxicological drug screening. Analytical chromatographic databases of toxicologically important drugs have been produced for TLC (1-3) and GC (4-6), and attempts have been made to produce similar databases for HPLC (7, 8) . HPLC has for many years been used as a complementary Figure 1 . Chromatogram showing the elutJon order of the reference mixture containing the markers used to calculate the basic and acidic/neutral RI scales based on the extended gradient.
Reproduction (photocopying) of editorial content of this journal is prohibited without publisher's permission. method to GC because it can separate a wider range of compounds without the need for derivatization steps of certain highly polar and thermolabile drugs and metabolites. The system described here uses reversed-phase HPLC (RP-HPLC) which has become the most common method of separation (9) . There are various RP-HPLC columns available based on different packing materials providing different selectivities. Octadecylsilane (ODS) columns are probably the most common type in routine use; however, we have used columns modified with both octadecyl and cyanopropyl (OD/CN) silica, which has been shown to provide a possible selectivity advantage over ODS (10) . As the column packing material is not of the basedeactivated type, an amine modifier (triethylammonium) is used to promote the optimal chromatography of basic compounds. Diode-array ultraviolet detectors (DAD) record the absorbance of compounds over a range of wavelengths (e.g., 200-595 nm) as they pass through the detector flow cell, thus allowing the on-line acquisition of ultraviolet (UV) spectra (11) (12) (13) . HPLC linked with DAD detection (HPLC-DAD) is a very important tool in the identification of compounds; however, as some classes of drugs (e.g., barbiturates) may exhibit similar UV spectra, it is desirable to have a second parameter for identification, such as retention index or relative retention time. It is unusual for a substance to have an absolute retention time that remains constant either over a period of time (because of a gradual loss of stationary phase) or between different batches of columns with nominally identical packing material. In order to account for this variability, retention index (RI) can be used as a method of correction. RIs are based on the relationship between a substance's retention time and those of a number of reference compounds (markers). The retention times of other substances are converted to RI values by linear interpolation between the reference compounds. Most standardized GC methods use RI values based on the retention times of a homologous series of hydrocarbons. RI-based HPLC systems have used hydrocarbons (14) (15) (16) (17) , single drug markers (18, 19) , and, recently, 1-nitroalkanes (20, 21) . For this system, a number of acidic/neutral and basic drugs which eluted at regular intervals were used as retention markers, providing separate RI scales for acidic/neutral and basic drugs; this was shown to be advantageous in a previous investigation (10) .
HPLC screening systems providing large databases of drugs have been published, such as the Bogusz et al. (7) system and the automated REMEDi system marketed by Bio-Rad (8) . How- ever, none have provided the analytical toxicologist with a definitive system for general drug and metabolite screening that is both reliable and reproducible with a high resolving power. Previous studies (10) have shown that this RP-HPLC-DAD screening system based on an OD/CN column exhibits a greater degree of reproducibility than the similar drug screening system developed by Bogusz et al. (7) . The aim of this paper is to illustrate the effectiveness of the present system in routine analytical toxicology through its application to a number of clinical and forensic investigations. Figure 3 . Results of an extended gradient drug screen performed on a urine specimen using a 1-chlorobutane basic back extraction into 0.05M HzSO4. Peaks were identified as dothiepin and metabolites by comparing lhe UV spectra, using the RI database for confirmation.
Experimental Chromatographic equipment
Experiments were performed using an M480 high-precision pump, column oven, Gina 500 autosaropler, and a UVD340S DAD, all from Gynkotek (HPLC Technologies, Macclesfield, Cheshire, U.K.), and an X-Act four-channel degasser from Jour Research. Four Spherisorb $50D/CN 4.6 x 150-ram cartridge columns (Phase Sep Ltd., U.K.), protected by 4 x 10-ram guard columns of Spherisorb $5ODS2 were used for the studies. A saturation column was not used. Data acquisition was handled by a Gynkosoft software package running on an Elonex 560/I 60MHz Pentium PC with the DAD recording spectral data between 200 nm and 595 nm.
The GC system was an Ai GC 94 (Ai Cambridge Ltd., Cambridge, U.K.) fitted with a nitrogenphosphorus-specific detector (NPD) and a flame ionization detector (FID). The GC was fitted with a CTC Analytics A200SE autosampler (Zwingen, Switzerland). The column was an HP5 25-m x 0.32-ram capillary column with a DB5 phase of 0.52-pro film thickness (Hewlett-Packard, Bracknell, U.K.).
Materials
The 1.0M triethylammonium phosphate buffer (pH 3.0) was supplied by Fluka (Gillingham, Dorset, U.K.), and the HPLC-grade acetonitrile and HPLC-grade methanol were supplied by Rathburns Chemicals Ltd. (Walkerbum, Scotland) .
The drugs used as standards in the investigation were obtained from various pharmaceutical companies or purchased from Sigma Chemicals (Poole, Dorset, U.K.). The benzophenones were produced by acid hydrolysis of a methanolic solution of benzodiazepine with concentrated HCI followed by evaporation to dryness and reconstitution with HPLC-grade methanol.
A mixture of each of the reference drug standards was made to a concentration of 0.1 mg/mL in HPLCgrade methanol, except for ephedrine which was 0.25 mg/mL. The injection volume was 10 IlL. The various drug standards were dissolved in HPLC-grade methanol to a concentration of 1 mg/mL and diluted before injection to a final concentration of 0.1 mg/mL with methanol. The injection volume was 10 IlL.
Extraction methods for biological specimens
Whole blood, serum, plasma, and urine samples were extracted using in-house liquid-liquid extraction techniques associated with existing GC and HPLC systems. Figure 4 . Results of an extended gradient drug screen performed on a blood specimen using a 1-chlorobutane basic back extraction into 0.05M H2SO 4. Significant peaks were identified to be propranolol, citalopram, and a citalopram metabolite by comparing the UV spectra, using the RI database for confirmation.
For basic drugs, 200 pL 0.2M Na2CO 3 buffer was added to 500 IlL of sample followed by 5 mL of 1-chlorobutane. After shaking for 3 rain and centrifugation at 2700 rpm for 3 rain, the supernatant was transferred to a second tube and drugs were extracted into 100 pL 0.05M H2SO 4. Twenty microliters of the acid layer was transferred into a vial for injection. For acidic/neutral drug extractions, 500 pL 0.05M H2SO 4 was added to 500 IlL of sample with 5 mL chloroform added as the extractant, followed by shaking for 3 rain and centrifugation at 2700 rpm for 3 min. The supernatant was filtered through chloroform-saturated filter paper, evaporated to dryness, and reconstituted with 100 IlL methanol before injection. The injection volume was 20 IlL.
Method
A single-step gradient elution was performed using a mixed mobile phase. Mobile phase A consisted of 700 mL 99.9% HPLC-grade acetonitrile with 25 mL 1M triethylammonium phosphate buffer (pH 3.0) diluted with 275 mL HPLC-grade water to a final concentration of 25mM buffer and 70% acetonitrile. The resulting mixture was not pH adjusted, and the resultant pH, as measured by a pH meter, was 4.0. Mobile phase B consisted of 25 mL 1M triethylammonium phosphate buffer diluted with 975 mL HPLC-grade water to a final concentration of 25mM buffer. This mixture was not pH adjusted and was therefore pH 3.0.
The elution conditions for the extended gradient were achieved using a 2 mL/min flow rate of 0-70% acetonitrile over 25 rain and held at 70% acetonitrile for 5 min. It was found that an effective equilibration time was required because of baseline disturbances in the subsequent run. To achieve this, the eluent was held at 70% acetonitrile for an additional 5 min, then reduced from 70 to 0% acetonitrile over 5 rain, and finally held at 100% buffer (mobile phase B) for 5 min. This gave a total run time of 45 min between injections, with data acquisition during the first 30 min. The column temperature was maintained at 25~
The elution conditions for the rapid gradient were achieved using a 2 mUmin flow rate of 0-70% acetonitrile over 15 rain and held at 70% acetonitrile for 3 rain. For equilibration purposes, the eluent was immediately held at 100% buffer (mobile phase B) for 4 rain. This gave a total run time of 22 rain between injections, with data acquisition during the first 18 rain. The column temperature was maintained at 25~
Calculation of RI values
A mixture containing five acidic/neutral and five basic drug markers was selected (Figure 1 and Table I ) which provided an arbitrary but linear retention index scale during gradient elution. The relative retention indices were calculated for acidic and neutral drugs by interpolation between acidic drug standards and for basic drugs by interpolation between basic drug standards.
[] values were calculated using the following formula after the position of the substance had been determined between two of the markers:
RI value = ( tR-t I [ t2-t I ) • 100 + RIl
where t R is the retention time of the toxicological substance (min), tl is the retention time of the first marker (min), t2 is the retention time of the second marker (min), and RI1 is the RI value of the first marker.
The RI values for substances eluting outside the retention ranges of the reference markers, were calculated as follows. For substances eluting earlier than Marker I (i.e., 100 RI units),
where tR is the retention time of the toxicological substance (min) and T1 is the retention time of Marker 1 (e.g., ephedrine or paracetamol) (rain). For substances eluting later than Marker 5 (i.e., 500 RI units),
where tn is the retention time of the toxicological substance (rain) and T5 is the retention time of Marker 5 (e.g., amiodarone or lorazepam benzophenone) (min).
The UV spectra and RI values of over 250 toxicological substances were acquired based on the extended gradient and compiled to form the RI and UV spectral database.
Results and Discussion

Development of a fast-screening technique
The gradient elution ramp of 0-70% acetonitrile in 25 min was originally chosen because it provided optimal resolution of closely eluting drugs, but the results could not be analyzed until data acquisition was complete (after 30 rain). This is an acceptable waiting time for routine clinical and forensic work during the day. However, for emergency drug screening, it was decided to attempt development of a fast-screening method for HPLC-DAD analysis that would allow rapid acquisition of results and hence (in the case of clinical toxicology) improve patient management because the correct supportive or antidotal treatment could be given much sooner with a more rapid identification of the drugs involved.
Gradient studies
Gradient studies were performed to achieve the fastest elution ramp possible without losing too much sensitivity and resolution. The original 0-70% acetonitrile elution gradient of 25 min was initially reduced to 10 min; however, this showed an unacceptable loss in resolution, so the elution ramp was increased to 15 min. Figure 5 . Results of an extended gradient clrug screen performed on a urine specimen using a 1-chlorobutane basic back extraction into 0.05M H2SO 4. Significant peaks were identified as caffeine, metoclopramide, and clenbuterol by comparing the UV spectra, using the RI database for confirmation. To study in greater detail the effect of increasing the elution ramp, 11 basic and 9 acidic/neutral drugs that eluted across the whole RI range were chosen (based on the extended gradient R] scales). First, the reference mix containing the 10 RI reference markers was run using both the 25 min and the 15 rain gradients.
The RI values for the 20 chosen drugs were then calculated for the two elution ramps and compared (Table II) Figure 6 . Results of a rapid gradient drug screen performed on a blood sample using an acidic chloroform extraction. Significant peaks were identified as chlordiazepoxide, demoxepam, temazepam, and carbamazepine by comparing the UV spectra, using the RI database for confirmation.
values could still be used in addition to the UV spectral library as a method of identification. It was therefore decided that the 0--70% acetonitrile gradient over 15 min would be suitable for a fast-screening method. Allowing for a 4 rain equilibration time, analytical results can be interpreted in 18 min. This is a more acceptable turnaround time for the generation of emergency drug screening results. In non-urgent situations, however, the use of the extended gradient, which provides greater resolution of closely eluting compounds, is preferred. The presence of a slight baseline disturbance was observed in the RI range of 100-200, particularly when analyzing urine samples containing many acid species. Further gradient studies were performed in an attempt to reduce the interference caused by this disturbance and hence increase the sensitivity of the method for drugs eluting in the affected region. This involved the development of a rapid 4-70% acetonitrile elution gradient over 15 rain, which appeared to reduce the disturbance, presumably due to the initial introduction of acetonitrile in the mobile phase. However, because of the initial presence of acetonitrile, the retention of the early eluting compounds (e.g., amphetamines) was greatly reduced, thus reducing the usefulness of the gradient for general drug screening. It was therefore decided to use this method only for urine specimen screening of later eluting drugs such as thiazides (e.g., chlorothiazide) and other diuretics.
Forensic and clinical applications of the system
To date, this recently developed system has been applied to over 100 cases encompassing both forensic and clinical investigations in both its rapid and extended formats. In most of the investigations, it has been used in conjunction with a routine NPD capillary GC screening method based on FID hydrocarbon RI values. In several cases, however, the diode-array facility has been the only method capable of identifying certain compounds such as diuretics and sulphonylureas. Figure 2 shows the results of a rapid screen for thiazides in a urine sample taken 2.5 h after a single 50-rag dose of chlorothiazide. Chlorothiazide and caffeine were detected by matching the RI values and UV spectra. Because of their polar nature, diuretic compounds are not amenable to GC and would not be detected in a GC or gas chromatographic-mass spectrometric (CC-MS) unknown-drug screen without derivatization. The confirmed presence or absence of any drug is obviously an important factor in clinical investigations or forensic investigations.
The following examples illustrate further advantages and applications of the system for clinical and forensic investigations.
Case study I (clinical application).
A 20-year-old female was admitted into the intensive care ward after taking a suspected overdose of Prothiaden | which contains the tricyclic antidepressant drug dothiepin. Urine was collected within hours of suspected ingestion. Figure 3 shows the results of the urine drug screen, which reveals dothiepin and its metabolites. These were identified because of the matching of the RI values and the UV spectra (Table IlI) . It can be seen from the UV spectra of the compounds that the principal dothiepin metabolite, N-desmethyl dothiepin (nordothiepin), has a virtually identical spectrum to the parent drug. Therefore, identification can only be determined by comparing calculated RI values with the RI database. This also applies to the dothiepin and nordothiepin sulfoxides, which also have identical spectra. Such similarities highlight the requirement for a database of RI values that includes metabolites in addition to the parent compounds.
The presence of dothiepin metabolites (nordothiepin, nordothiepin sulfoxide, and dothiepin sulfoxide) and hence the ratio of metabolite to parent drug is one of the most important factors in determining the possible cause of death in forensic cases (22) . Therefore, it is important that all drug metabolites can be detected.
Case study 2 (forensic application).
The deceased was a 65-year-old female who had suffered from clinical depression and died from injuries sustained after jumping from a window. She had been prescribed citalopram (a new SSRI-selective serotonin reuptake 5oo ~u inhibitor/antidepressant), thioridazine, and zolpidem. A blood specimen was taken from the 4oo right femoral vein postmortem. Figure 4 shows the results of the drug screen performed as part of the forensic investigation. It 300 was found that citalopram, a citalopram-associated peak, and propranolo/were present in blood. 2oo Although reference standards of citalopram metabolites were not available in the laboratory at the time of this analysis, it was possible to ~oo assign a probable identity of a citalopram metabolite (desmethylcitalopram) to one of the peaks on the basis of an identical spectral match o of the parent compound. It is frequently possible -5o to identify probable drug metabolites in this way o. o (which is one of the strengths of HPLC-DAD), because some phase-one metabolic transformations (especially N-desalkylation and sometimes hydroxylation) do not alter the UV chromophore of a drug. This provides HPLC-DAD with a clear advantage over GC systems based on NPD detection, which do not have a secondary identification tool such as UV spectral data, particularly when a drug metabolite standard is not available. Even GC-MS is unlikely to provide such presumptive identification of drug metabolites unless the compounds have been entered into the spectral database.
Case study 3 (clinical application).
A 29-yearo]d male body builder was admitted with renal impairment and symptoms suggestive of the non-steroidal, sympathomimetic agent clenbuterol, which also has anabolic properties. The patient had been taking the anabolic agent Anabol (norclostebol acetate), which is structurally unrelated to clenbuterol. He had also been prescribed metoclopramide. A selection of tablets and a urine sample were provided for analysis. A drug screen was requested in order to identify the constituent(s) of the tablets and also identify and confirm the presence of drugs in the urine.
The tablets were crushed and extracted for HPLC-DAD analysis using the 1-chlorobutane extraction method. It was clear from the chromatogram and peak purity analysis that the tablet contained only a single compound. A clenbuterol hydrochloride standard was also analyzed using the system, and this produced an identical chromatogram with an identical spectrum and RI value to that of the tablet. Figure 5 shows the results of the drug screen performed on the urine sample. It can be seen that caffeine, metoclopramide, and clenbuterol were detected. The presence of metoclopramide was expected, and caffeine regularly appears in subjects who have ingested caffeinated beverages. The presence of clenbuterol was confirmed both spectrally and by RI value, thus the diagnosis could be confirmed, allowing the appropriate treatment to be given. Without the option of HPLC-DAD, the identification of the substance in the tablet and the urine as clenbuterol Figure 7 . Results of an extended gradient drug screen performed on a blood specimen using a 1-chlorobutane basic back extraction into O.05M H2SO 4. Peaks were identified as dihydrocodeine, amitriptyline, and the corresponding metabolites by comparing the UV spectra, using the RI database for confirmation. Results of an extended gradient drug screen performed on a blood specimen using a 1-chlorobutane basic back extraction into 0.05M H2SO 4. Peaks were identified as dihydrocodeine, amitriptyline, and the corresponding metabolites by comparing the UV spectra, using the RI database for confirmation.
would have been difficult because it was not detected by the GC screening procedure nor by any of the other analytical methods used for routine unknown-drug screening, such as TLC.
Case study 4 (forensic application). The deceased was found at a recreation ground with facial injuries. A drug screen was performed to determine any drug involvement. He had been prescribed the benzodiazepines temazepam and chlordiazepoxide and the anti-convulsant carbamazepine. A postmortem blood specimen was taken.
The results of a blood drug screen for acidic and neutral compounds are shown in Figure 6 . It can be seen that by both spectral and RI matching (Table IV) that chlordiazepoxide, demoxepam, temazepam, and carbamazepine were present. In addition to these, a possible chlordiazepoxide metabolite (norchlordiazepoxide) was detected ( Figure 6) ; however, its presence was difficult to confirm by UV spectral matching because of the apparent low concentration of this compound in the sample. The chlordiazepoxide metabolite demoxepam has a similar UV spectrum to that of the parent drug but with a bathochromic shift. This particular drug screen was performed using the rapid elution ramp and shows the applicability of the RI database for screening based on both the extended and rapid gradient methods.
Case study 5 (forensic application).
The deceased had suffered from alkylosing spondylitis, and it was thought that he died from a drug overdose. He had been prescribed various drugs, including dihydrocodeine, methotrexate, nizaditine, and the tricyclic antidepressant drug amitriptyline. Postmortem blood and urine specimens were taken.
The results of a urine HPLC-DAD screen for basic drugs (Figure 7) show the presence of dihydrocodeine, amitriptyline, and their associated metabolites (nordihydrocodeine, nortriptyline, etc.). In addition to the primary amitriptyline metabolite (nortriptyline), the cis-and trans-isomers of 10-hydroxyamitriptyline and 10-hydroxynortriptyline were also detected, along with a number of amitriptyline-associated compounds that had identical spectra to the parent drug. It is often the case that such metabolites are present in urine in large concentrations relative to the parent compound because of extensive hydrolysis prior to conjugation and excretion. It is therefore important that such metabolites and any other associates of amitriptyline can be detected in order to determine if amitriptyline has been taken at any time.
Case study 6 (forensic application). The deceased, a known user of crack cocaine and heroin, died unexpectedly following a dental extraction procedure that involved the administration of lignocaine as a local anesthetic. Blood and urine specimens were taken postmortem.
It can be seen from the results of the urine drug screen that a number of commonly abused drugs, such as ephedrine, amphetamine, and cocaine, were present in addition to the lignocaine ( Figure 8 ); these were identified by spectral and RI matching. Many of these drugs were also detected using an FID-NPD capillary GC screening method for basic drugs; however, this method did not detect the presence of a low concentration of the heroin metabolite, 6-monoacetylmorphine. This is another example of the ability of the system to detect important metabolites that may have a bearing on the case, whether it be clinical or forensic, because drug metabolites can be used Time (min) as markers indicating the injection or ingestion of drugs. These results also show the advantage of this HPLC-DAD system for general drug screening. As drugs of abuse are becoming increasingly prevalent in society, it is important that such drugs be incorporated into unknown-drug screening. 
Quantitation of drugs and metabolites in clinical and forensic investigations
Drug screening is a qualitative technique for the identification the presence of drugs. For quantitative HPLC analyses of compounds identified by screening, it is generally more efficient to use isocratic chromatography. Suitable chromatographic conditions and appropriate internal standards can be determined from the RI database. All of the compounds to be analyzed (including the internal standard) must exhibit baseline separation in order to calculate their accurate concentrations. The RI database is used to predict the elution order and degree of separation (resolution) of the drugs and enables an appropriate internal standard to be selected which will not coelute or interfere with the separation of the other peaks. The appropriate mobile phase composition (e.g., acetonitrile concentration) can be derived from the database RI values (e.g., an RI value of 300 would correspond to an approximate acetonitrile concentration of 40%). The RI database is therefore a valuable tool for determining a strategy for drug/metabolite quantitation.
mln Figure 8 . Results of an extended gradient drug screen performed on a urine specimen using a 1 -chlorobutane basic back extraction into 0.05M H2SO 4. Various common drugs of abuse were identified in addition to lignocaine and metabolites by comparison of the UV spectra, using the RI database for confirmation.
Conclusion
The HPLC-DAD system has been extensively shown to be an efficient and practical method for both clinical and forensic toxicological investigations, particularly in its ability to screen for a wide range of compounds including benzodiazepines, paracetamol, drugs of abuse (e.g., opiates, amphetamines, and cocaine), diuretics, sulfonyureas, tricyclic antidepressants, and barbiturates. It also provides an additional application for devising and performing quantitative analyses. It can be applied to the screening of basic, acidic, and neutral drugs, providing very reproducible results even under the rapid elution conditions of emergency drug screening. It has provided support to the existing methods of analysis and has proved necessary for routine and forensic investigations because of its ability to detect several classes of drug that cannot be easily detected using existing GC, GC-MS, and TLC screening methods. Using the diode-array facility, it is also possible to detect any probable metabolites which are not available as drug standards by comparing the UV spectrum of the proposed metabolite and the parent compound. The system and the RI database could also be combined with additional techniques such as liquid chromatography-mass spectrometry, thus providing an extremely powerful identification tool that combines RI values, UV spectra, and ion fragmentation spectra. The database is being constantly expanded to include a wider range of toxicologically significant compounds and their metabolites, and it already provides a more relevant toxicological database than other published systems for our routine casework. It is anticipated that further work involving interlaboratory studies will demonstrate that the system can be applied in any laboratory using identical conditions to those described in this paper. Overall, the system provides an efficient and reproducible analytical method for general drug screening which can be used as a complementary method to TLC and GC or GC-MS techniques.
